MCM
ACRS icon

MAI Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

MAI Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4 Buy
+1
New +$3 ﹤0.01% 4995
2025
Q1 		– Sell
-1,500
Closed -$3.72K – 3441
2024
Q4 		$3.72K Buy
+1,500
New +$3.73K ﹤0.01% 2871

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MAI Capital Management's ACRS Position: Q1 2026 in Review

MAI Capital Management opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 1 share worth $4. The stake represents ﹤0.01% of the portfolio and ranks #4995 among its holdings. This is a return to the name: MAI Capital Management previously reported a position in ACRS as recently as Q4 2024.

MAI Capital Management first reported a position in ACRS in Q4 2024 and has held it in 2 quarters since. The position peaked at $3.72K in Q4 2024. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • MAI Capital Management held 1 share of Aclaris Therapeutics worth $4 as of Q1 2026.
  • Aclaris Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4995 holding.
  • MAI Capital Management first reported a position in Aclaris Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • MAI Capital Management's Aclaris Therapeutics position peaked at $3.72K in Q4 2024.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.